Trials
ClotChip® received FDA breakthrough device designation in March 2020, and is currently in clinical trials. A list of feasibility studies on the ClotChip® sensor include the following:
ClotChip® correlation to peak-trough blood concentration in both apixaban & rivaroxaban subjects
The U.S. Department of Veterans Affairs, Cleveland, OH
Status: enrollment closed; N = 24
ClotChip® Sensitivity in Hemophilia – In Vivo & Ex Vivo analyses
University Hospitals of Cleveland – Rainbow Babies & Children Hospital, Cleveland, OH
Status: enrollment closed; N = 100
ClotChip® Sensitivity in Target Specific oral Anticoagulants
The U.S. Department of Veterans Affairs, Cleveland, OH
Status: enrollment closed; N=176
Assessment of whole blood coagulation with a microfluidic dielectric sensor published in Journal of Thrombosis and Haemostasis, 16: 2050–205